Why the Rare Vaccine-Linked Clots Happen, Explained

An international study of 100 VITT patients shows the condition starts with antibodies that target an adenovirus protein; a single antibody mutation then makes them bind platelet factor 4 strongly, and a common immune gene variant shapes the response. VITT requires both a hereditary variant and a rare antibody mutation, explaining its rarity and offering clues for designing safer adenovirus-based vaccines in the future.